Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serelaxin (Primary) ; Heart failure therapies; Heart failure therapies
  • Indications Acute heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms RELAX-AHF-ASIA
  • Sponsors Novartis Pharma KK; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Apr 2022 Results of a retrospective patient level analysis from 4 randomized controlled trials (NCT02064868, NCT02007720, NCT01870778, NCT00520806) assessing serelaxin in acute heart failure published in the Circulation: Heart Failure
    • 05 Jul 2017 Status changed from recruiting to discontinued.
    • 06 Jun 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top